Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $25M Series A (Mar 2024). 180+ countries covered. Positioned as the low-cost alternative to Deel and Rippling for global EOR and contractor management. ARR grew 10x post-seed.
Remofirst is a global employer of record (EOR) and contractor management platform that covers 180+ countries, positioned as the cost-competitive alternative to Deel and Rippling for companies that need global employment infrastructure without the premium pricing of the category leaders. The company raised $25 million in Series A financing in March 2024 and grew ARR 10x in the period following its seed round, establishing itself as the primary Deel challenger for price-sensitive buyers.
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.